Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.47 |
| ▸ | DDX3X | O00571 | 4/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 2/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.40 |
| ▸ | CSGALNACT1 | Q8TDX6 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3388395 | 0.88 | NPC1 (0.46) | CHRNA7KDM4EMEN1KMT2ANPC1 | |
| SCHEMBL3390148 | 0.87 | CHRNA7 (0.48) | DGAT1CHRNA7KDM4EMEN1KMT2A | |
| SCHEMBL3393090 | 0.86 | NPC1 (0.48) | DGAT1CHRNA7KDM4EMEN1KMT2A | |
| SCHEMBL3390544 | 0.86 | ABCB1 (0.44) | CHRNA7KDM4ENPC1RAB9ACCR3 | |
| SCHEMBL3388415 | 0.86 | PDE5A (0.43) | DGAT1CHRNA7MEN1KMT2ANPC1 | |
| SCHEMBL3391378 | 0.86 | CHRNA7 (0.41) | CHRNA7NPC1RAB9APOLBTP53 | |
| SCHEMBL3390921 | 0.84 | CHRNA7 (0.54) | DGAT1CHRNA7MEN1KMT2ARAB9A | |
| SCHEMBL3389457 | 0.83 | ABCG2 (0.47) | CHRNA7MEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL3391632 | 0.83 | HPGD (0.47) | CHRNA7KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL3393545 | 0.81 | DGAT1 (0.46) | DGAT1CHRNA7KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713810-B1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH AS (DK) | 2010-12-29 | — | — | EP | claimed |
| US-20100130482-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | PETERS DAN | 2010-05-27 | — | — | US | claimed |
| US-20080227772-A1 | Diazabicyclic Aryl Derivatives as Nicotinic Acetylcholine Receptor Ligands | NEUROSEARCH A/S | 2008-09-18 | — | — | US | claimed |
| EP-1713810-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2006-10-25 | — | — | EP | claimed |
| WO-2005075482-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2005-08-18 | — | — | WO | claimed |
| EP-1713810-B1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH AS (DK) | 2010-12-29 | — | — | EP | disclosed |
| US-20100130482-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | PETERS DAN | 2010-05-27 | — | — | US | disclosed |
| US-20080227772-A1 | Diazabicyclic Aryl Derivatives as Nicotinic Acetylcholine Receptor Ligands | NEUROSEARCH A/S | 2008-09-18 | — | — | US | disclosed |
| EP-1713810-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005075482-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130482-A1 | DIAZABICYCLIC ARYL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA6, CHRNA10, CHRNA2 | DGAT1 1693/4885DDX3X 2725/4885CHRNA7 5/4885 |
| US-20080227772-A1 | Diazabicyclic Aryl Derivatives as Nicotinic Acetylcholine Receptor Ligands | CHRNA6, CHRNA10, CHRNA2 | DGAT1 1693/4885DDX3X 2725/4885CHRNA7 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.